Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INMARK: Nintedanib Biomarkers in IPF
NCT02788474Phase 4Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2016
- Primary completion
- Aug 2017
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 13
01
Overview
A Phase 4 trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Started Jun 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02788474.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02788474.